首页 蛋白库 基因库 产品 会员服务
位置：首页 > 产品库 > dBET1
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
dBET1
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
dBET1图片
CAS NO:1799711-21-9
包装与价格：
包装价格(元)
2mg询价
5mg询价
10mg询价
25mg询价
50mg询价

dBET1 是一种 PROTAC，通过 Cereblon 和 BRD4 的配体连接，EC50 为 430 nM。 dBET1 是一个 PROTAC，由 (+)-JQ1 组成，通过链接器链接到 NSC 527179。
Cas No.1799711-21-9
别名2-((S)-4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-F][1,2,4]三唑并[4,3-A][1,4]二氮杂卓-6-基)-N-(4-(2-((2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-4-基)氧基)乙酰氨基)丁基)乙酰胺
Canonical SMILESO=C(NCCCCNC(COC1=CC=CC(C(N2C(CC3)C(NC3=O)=O)=O)=C1C2=O)=O)C[C@H]4C5=NN=C(C)N5C6=C(C(C)=C(C)S6)C(C7=CC=C(Cl)C=C7)=N4
分子式C38H37ClN8O7S
分子量785.27
溶解度DMSO : ≥ 50 mg/mL (63.67 mM);Water :< 0.1 mg/mL (insoluble)
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

dBET1 is a potent BRD4 protein degrader based on PROTAC technology with an EC50 of 430 nM.

Treatment with dBET1 down regulates MYC and PIM1 transcription. Degradation of BRD4 by dBET1 is associated with a more potent apoptotic consequence in MV4;11 cell line. Significantly increased apoptosis after only 4 h of dBET1 treatment is enhanced at 8 h. dBET1 also induces a potent and superior inhibitory effect on MV4;11 cell proliferation at 24 hours (measured by ATP content, IC50= 0.14 uM, compare to IC50= 1.1 uM with JQ1)[1].

Administration of dBET1 attenuates tumor progression as determined by serial volumetric measurement, and decreases tumor weight assessed post-mortem. Acute pharmacodynamic degradation of BRD4 is observed four hours after a first or second daily treatment with dBET1 (50 mg/kg IP). A statistically significant destabilization of BRD4, down regulation of MYC and inhibition of proliferation is observed with dBET1 compare to vehicle control in excised tumors. Two weeks of dBET1 is well tolerated by mice without a meaningful effect on weight, white blood count, hematocrit or platelet count[1].

References:
[1]. Winter GE, et al. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 2015 Jun 19;348(6241):1376-81.

 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024